Jiang Runxue, Shen Jianglun, Wang Xia, Chen Shuohua, Wu Shouling, Cai Haifeng
Department of Oncology Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Department of Gynaecology, Tangshan Hongci Hospital, Tangshan, Hebei 063000, P.R. China.
Mol Clin Oncol. 2024 Jul 12;21(3):64. doi: 10.3892/mco.2024.2762. eCollection 2024 Sep.
The present study aimed to assess the risk of postmenopausal breast cancer in women based on a combination of body mass index (BMI) and high-sensitivity C-reactive protein (hs-CRP) levels. A total of 20,400 participants were investigated as part of the 'Kailuan Study' clinical trial. Participants were classified into four groups based on BMI (BMI ≥24 or <24 kg/m) and hs-CRP level (hs-CRP ≥3 or <3 mg/l). Cox proportional hazards models were used to evaluate the association between the combination of BMI and hs-CRP and the risk of postmenopausal breast cancer. A total of 19,540 participants met the inclusion criteria. The median follow-up time was 14.97 years, with a cumulative follow-up period of 283,599.43 person-years. Among the participants, 269 individuals were diagnosed with postmenopausal breast cancer. Individuals with a high BMI (BMI ≥24 kg/m) and a high hs-CRP level (hs-CRP ≥3 mg/) had a greater risk of postmenopausal breast cancer compared with individuals with a low BMI (BMI <24 kg/m) and a low hs-CRP level (<3 mg/l) (hazard ratio, 1.75; 95% confidence interval, 1.25-2.47). The sensitivity analysis showed findings consistent with the primary results. In conclusion, the combination of high BMI and high hs-CRP level is associated with an increased risk of postmenopausal breast cancer. The present study is part of the Kailuan Study. Trial registration number: ChiCTRTNCR11001489 (Chinese Clinical Trial Registry, https://www.chictr.org.cn/showproj.html?proj=8050). Date of registration: 19/07/2015.
本研究旨在基于体重指数（BMI）和高敏C反应蛋白（hs-CRP）水平的组合评估绝经后女性患乳腺癌的风险。作为“开滦研究”临床试验的一部分，共对20400名参与者进行了调查。参与者根据BMI（BMI≥24或<24kg/m²）和hs-CRP水平（hs-CRP≥3或<3mg/l）分为四组。采用Cox比例风险模型评估BMI和hs-CRP组合与绝经后乳腺癌风险之间的关联。共有19540名参与者符合纳入标准。中位随访时间为14.97年，累积随访期为283599.43人年。在参与者中，有269人被诊断为绝经后乳腺癌。与低BMI（BMI<24kg/m²）和低hs-CRP水平（<3mg/l）的个体相比，高BMI（BMI≥24kg/m²）和高hs-CRP水平（hs-CRP≥3mg/l）的个体患绝经后乳腺癌的风险更高（风险比，1.75；95%置信区间，1.25-2.47）。敏感性分析结果与主要结果一致。总之，高BMI和高hs-CRP水平的组合与绝经后乳腺癌风险增加相关。本研究是开滦研究的一部分。试验注册号：ChiCTRTNCR11001489（中国临床试验注册中心，https://www.chictr.org.cn/showproj.html?proj=8050）。注册日期：2015年7月19日。
